ReviewMolecular diagnosis & therapy2015
Can genomic medicine improve financial sustainability of health systems?
Review in Molecular diagnosis & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Conceptualising 'Benefits Beyond Health' in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis.PharmacoEconomics · 2021Review
- Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network.JCO clinical cancer informatics · 2019Article
- A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Review
- Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017Article
- Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study.BMJ open · 2016Observational
- Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in Taiwan.BMJ open · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent years have seen increased use of genomic technologies in a variety of research and clinical settings. Genomic medicine is not a cost-containment measure per se, but is viewed as having the potential to bend the healthcare cost curve. Currently, it is unknown how systematic adoption of genomic medicine in clinical practice will impact healthcare costs. This article discusses the potential economic impact of genomic medicine and the challenges that lie ahead.
Indexed as
Identifiers
25862552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.